James is the CEO of Glass Pharms, a pioneering company in high-tech sustainable pharmaceutical cultivation. Glass Pharms, the first licenced producer of medical cannabis flower for CBPMs in the UK, operates a 2.4ha continuous cultivation facility able to achieve UK microbial standards without irradiation. James trained as a chemist but spent most of his career leading technology companies, building start-ups and in large corporates. He brings a fresh pair of eyes and scientific approach to pharmaceutical cannabis.
James Duckenfield, CEO of Glass Pharms®, examines what irradiation changes in medical cannabis flower, what it leaves behind, and why understanding microbial quality requires a closer look at the science.
Cannabis research has historically concentrated on THC and CBD, and for good reason.
As new national guidance instructs officers to treat medical cannabis users as patients first, James Duckenfield, CEO of Glass Pharms, reflects on what training police forces has taught him about the gap between the law and the general understanding of the legal landscape, and how the industry as a whole can help close it.
As the UK’s medical cannabis industry continues to come under fierce scrutiny from the country’s mainstream media, James Duckenfield, CEO of UK-based cannabis cultivator Glass Pharms, argues that the focus should be on ensuring compliance with the existing regulatory framework rather than sensationalising a prescribing rate that remains a small fraction of demonstrable clinical need.
